


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on March 9, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Patent Application
Docket No. ARS-124
Serial No. 10/573,625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson
Serial No. : 10/573,625
Filed : March 28, 2006
Conf. No. : 9024
For : Therapeutic Uses of Chemokine Variants

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: